External broker reports(aggregated public sources), Mirae Asset Securities

Mirae Asset Securities

Leading full-service brokerage firm in Vietnam. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>Our target price for Celltrion is based on our 12-month forward EBITDA estimate of W1.87tr and a target EV/EBITDA of 27x.</li><li>Although we lowered our 2026 operating profit and EBITDA estimates by 10% and 7%, respectively, reflecting lower sales estimates for Zymfentra and other products, we lifted our target price to reflect a shift in our valuation base period (to 2026) and a change in the number of shares outstanding.</li><li>Over the past year, we have sharply reduced our 2025 Zymfentra sales forecast (from W1tr to W95.5bn; -90%) due to rising rebates and discounts in the US autoimmune therapy market and the drug’s slower-than-expected market penetration. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Our target price for Celltrion is based on our 12-month forward EBITDA estimate of W1.87tr and a target EV/EBITDA of 27x.Although we lowered our 2026 operating profit and EBITDA estimates by 10% and 7%, respectively, reflecting lower sales estimates for Zymfentra and other products, we lifted our target price to reflect a shift in our valuation base period (to 2026) and a change in the number of shares outstanding.Over the past year, we have sharply reduced our 2025 Zymfentra sales forecast (from W1tr to W95.5bn; -90%) due to rising rebates and discounts in the US autoimmune therapy market and the drug’s slower-than-expected market penetration. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Celltrion (068270 KS/Buy)Cost Ratio Continues to Improve

Celltrion Inc

Celltrion (068270 KS/Buy)Cost Ratio Continues to Improve